Main objective To assess respiratory sequelae after SARS-CoV-2 infection in hospitalized patients with severe pneumonia requiring oxygen supply and followed up for 6 months after hospital discharge (see primary and secondary outcomes).~Secondary objectives~To describe pulmonary sequelae according to :~the unit in which the patient was hospitalized,~the maximum oxygen flow rate required during hospitalization,~McCabe score,~age,~tobacco consumption,~biological data (e.g. blood count, CRP, fibrinogen, LDH, albumin, D-dimer, ferritin),~number of days from onset of symptoms to hospitalization,~co-morbidities (e.g. diabetes, hypertension, coronary artery disease/heart failure, mild to moderate COPD/respiratory failure, overweight),~concomitant treatments (e.g. non-steroidal anti-inflammatory drugs, corticosteroids, immunosuppressants, ACE inhibitors)~specific drug treatments administered to treat COVID-19 infection,~non-drug treatments (invasive ventilation, non-invasive ventilation, postural treatment) to manage respiratory disorders of COVID-19 infection.~To assess the impact of factors of social inequality on the severity of COVID-19 infection.~Conduct of research Patients who have been hospitalized for severe pneumonia due to CoV-2 SARS infection will be seen in consultation at approximately 3 and 6 months after hospital discharge, as per standard practice.
The objective of this multicenter observational study is to describe respiratory sequelae of COVID-19 patients hospitalized for severe pneumonia requiring oxygen supply.